• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • RedHill sees positive results for anti-MAP Crohn's drug pharmatimes
    July 31, 2018
    RedHill Biopharma has announced positive results from the first Phase III study of its Crohn's disease drug RHB-104 - making it the first global, double-blind, placebo-controlled study to demonstrates the efficacy of anti-MAP therapy in this hard-to-treat

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service